Loading...
•
Sep 30, 2024
Crinetics Q3 2024 Earnings Report
Crinetics reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Crinetics Pharmaceuticals reported its Q3 2024 financial results, highlighting the submission of the NDA for paltusotine and a strengthened balance sheet with a $575 million public offering. The company's focus remains on advancing its pipeline and preparing for the potential launch of paltusotine in 2025.
Submitted New Drug Application (NDA) for paltusotine for the treatment of acromegaly.
Strengthened balance sheet with $575 million public offering.
Selected development candidate in TSH antagonist program.
Data from CRN09682, the first drug candidate from novel Nonpeptide Drug Conjugate (NDC) platform to be presented at the North American Neuroendocrine Tumor Society (NANETS).
Crinetics
Crinetics
Forward Guidance
Crinetics anticipates additional data from the Phase 2 study of atumelnant in CAH by early 2025 and expects to finalize a Phase 3 protocol and initiate site startup activities for paltusotine in carcinoid syndrome by the end of 2024.